<?xml version="1.0" encoding="UTF-8"?>
<p id="para0007">This pandemic comes to the U.S. amid the opioid epidemic. Experiences from disasters like Hurricanes Katrina and Sandy have taught that illicit drug market disruptions place people who use drugs at risk for supply discontinuity, paraphernalia shortage, and social disconnection.
 <xref rid="bib0008" ref-type="bibr">
  <sup>8</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib0009" ref-type="bibr">
  <sup>9</sup>
 </xref> This will happen now. Furthermore, shutdowns will disrupt the ability to generate income necessary to support drug use. The result will be decreased use, loss of tolerance, and risk for overdose. Sharing or reusing scarce syringes will increase infectious diseases. Individuals who use opioids may be more interested in initiating medication for opioid use disorder. However, the treatments with the strongest evidence—methadone and buprenorphine—are not readily accessible in many parts of the country.
 <xref rid="bib0010" ref-type="bibr">
  <sup>10</sup>
 </xref> One million individuals with opioid use disorder did not have access to medication for the disorder in 2012.
 <xref rid="bib0011" ref-type="bibr">
  <sup>11</sup>
 </xref> In response to SARS-CoV-2, the Substance Abuse and Mental Health Services Administration has developed emergency regulations to support medication for opioid use disorder through telehealth
 <xref rid="bib0012" ref-type="bibr">
  <sup>12</sup>
 </xref> and temporarily waived the requirement for in-person physical examination to be able to initiate buprenorphine. To further increase access, the Drug Addiction Treatment Act of 2000 waiver should be suspended to allow any prescriber with a Drug Enforcement Administration license to prescribe buprenorphine. At a minimum, patient limits should be removed to allow existing buprenorphine prescribers to take on more new patients.
</p>
